Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ANTIBODY FORMATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources

Mechanism of inducing autologous antibody formation in nephrotoxic serum nephritis.

The role of the heterologous antibody fixed in the kidney was evaluated by means of transplantation of a nephritic kidney to a normal recipient in the rat. An intravenous injection of 0.5 ml of nephrotoxic serum could not induce distinct changes in the heterologous phase, but it could cause mild or moderate changes in the autologous phase. Titration of rat antibody to rabbit IgG according to passive hemagglutination test showed that rabbit IgG fixed in the transplant could induce autologous antibody formation with a similar intensity to nephrotoxic serum given intravenously, indicating that fixed antigen played the most important role in autologous antibody formation and other factors, such as the kidney-fixing rabbit IgG remained in circulation or fixed in other tissues and the gamma-globulin other than anti-kidney antibody, might be less important. It was unclear which antibody, fixed or dissociated from the transplant, played the more important role in stimulating antibody formation.

Animals↗

Antibody formation. IV. Formation of rapidly and slowly sedimenting antibodies and immunological memory to bacteriophage phi-X 174.

Injection of a sufficient dose of bacteriophage phiX 174 into guinea pigs results in the formation of rapidly sedimenting antibody molecules (19S), and later, slowly sedimenting molecules (7S). Above a threshold dose of antigen, the relative rate of 19S formation is maximal and dose-independent; below this dose, slower relative rates are obtained. The time for doubling the serum 19S level is as short as 6 to 8 hours, suggesting that the absolute rate of antibody formation per cell is increasing in addition to proliferation of antibody-producing cells. Synthesis of 19S after injection of 10(10) phiX virtually ceases at 10 days after which 19S antibody activity disappears from the circulation with a half-life of approximately 24 hours. A second injection of phiX on day 5 or 9 prolongs 19S synthesis, indicating that antigen not only can regulate the relative rate, but also is essential for continued synthesis of 19S. 19S synthesis is also prolonged in guinea pigs by injection of phiX with endotoxin or by 400 r whole body x-irradiation 24 hours after injection of phage into rabbits. The primary 7S response is not detected until approximately 1 week after immunization and relative rates are antigen-dependent. Primary 7S synthesis can continue for many months and leads to preparation for a secondary antibody response (immunological memory) during which only 7S is detected. In contrast, in animals that form precipitating 19S without detectable 7S, a second injection of phage 1 month later results in a second 19S response which closely resembles the first. These findings have led to the suggestion that formation of 19S does not lead to persisting immunological memory.

Animals↗

The Florey lecture, 1986. The regulatory biology of antibody formation.

The regulatory biology of antibody formation entered a new phase of study with the development of selective theories of immunity. The discovery of the 'one cell - one antibody' dogma and the demonstration that only a small minority of B cells possessed receptors specific for a given antigen were consistent with Burnet's clonal selection hypothesis, which was later formally proven by preparing antigen-specific lymphocytes and inducing clonal activation in vitro. Clonal analysis has aided precise study of immunoregulation for both B and T lymphocytes. Clonal activation of B cells in the absence of T cells is now possible with high cloning efficiency. It requires the combined action of certain antigens and growth factors, collectively termed B-cell stimulatory factors (BSFS). Single cell analysis has shown that most BSFS so far tested, in contrast to most claims in the literature, possess the capacity (in synergy with antigen) to: stimulate B cells out of the G0 phase into active cell cycle; promote sequential mitotic divisions; and induce differentiation to active secretory status. This is clearly true for IL-1, IL-2, and BSF-p2. These multiple actions resemble those of the colony-stimulating factors in haemopoiesis. Regulation of antibody production by T lymphocytes can also be profitably analysed in clonal systems. The immunoregulatory problem of tolerance can also be analysed by means of clonal techniques. Studies are summarized which indicate that T-cell-mediated suppression and functional silencing of toleragen-specific lymphocytes are both cooperatively involved in many tolerance models. For the B lymphocyte, tolerance can be induced without an actual deletion of the cell involved; rather, the tolerant cell appears to have received and stored a negative signal, rendering it unresponsive to normally immunogenic stimuli. Thus, a state termed 'clonal anergy' has been induced within the cell. Functional clonal deletion has also been noted in several models to T-lymphocyte tolerance, but here it is not known whether clonal anergy or actual death of the relevant cell is at work. Self-tolerance sufficient to be consistent with good health need not mean a total absence of cells with any degree of self-reactivity. Indeed, it is clear that some B cells capable of forming antibody with some degree of affinity for self-constituents exist in the body, and can be activated, for example by lipopolysaccharide. The requirement is to limit the amount, affinity and duration of autoantibody production. A model suggesting how this may be achieved is presented.

Animals↗

Effect of sodium fluoride on antibody formation in rabbits.

In the present study, the role of sodium fluoride on antibody formation in rabbits is assessed. Sixteen female albino rabbits were divided into four groups and were treated as follows: Group I: Animals immunized with transferrin and used as controls for group II; Group II: Animals immunized with transferrin and administered orally NaF (10 mg/kg body weight) daily for 9 months; Group III: Animals immunized with transferrin and served as controls for group IV; and Group IV: Animals administered with NaF at a dose of 10 mg/kg body weight daily for 9 months and then immunized with transferrin and fluoride treatment continued for another 9 months. Rabbits were bled just prior to immunization and subsequent bleeding was at weekly intervals. Circulating anti-transferrin titers were estimated. DNA and protein synthesis was determined by incorporating [3H]thymidine and [14C]leucine, respectively. The present report demonstrates that sodium fluoride inhibits antibody formation in rabbits. There is a threshold level of fluoride (0.78 ppm) in circulation which is responsible for the inhibitory effect on antibody formation. Inhibition of DNA and protein synthesis by NaF is also demonstrated. It is concluded that fluoride inhibits the antibody formation by decreasing the proliferation of lymphocytes and by inhibiting the protein synthetic ability of immunocytes.

Animals↗

Antibody formation against the cytotoxic proteins abrin and ricin in humans and mice.

Antibody formation may limit the therapeutic use of cancerostatic proteins. To study the significance of antibody formation against abrin and ricin, highly sensitive ELISA procedures for determination of anti-abrin and anti-ricin were developed. In mice treated weekly with therapeutic doses of ricin, antibodies appeared after 2-3 weeks and then rose rapidly, whereas after abrin treatment the antibody formation was slower. Ricin A-chain was found to be more immunogenic than either intact ricin or human serum albumin (HSA). Cyclophosphamide inhibited the antibody response to both abrin and ricin and a combination of cyclophosphamide and prednisolone totally inhibited both anti-abrin and anti-ricin formation during the 6-week observation period. In mice treated weekly with HSA, abrin treatment strongly reduced the anti-HSA formation, showing that abrin has an immunosuppressive effect which appeared to be stronger than that of cyclophosphamide. The existence of circulating antigen-antibody complexes could be demonstrated in the sera of toxin-treated mice by precipitation with polyethyleneglycol, whenever antibodies were detectable with ELISA. The life-span of animals given lethal ricin doses was appreciably enhanced in animals having antibody levels in excess of 10-20 ng/ml. In cancer patients treated i.v. every second week with therapeutic toxin doses, the 10-20 ng/ml levels of anti-ricin and anti-abrin were reached 6-8 weeks and 7-10 weeks after the first injection of ricin and abrin, respectively. The data indicate that the effective therapeutic use of abrin and ricin as single agents may be limited to these time frames, but that the period of effective use may be substantially prolonged if the toxins are given together with conventional cytostatic agents having immuno-suppressive activity.

Abrin↗

Differential requirement for B-memory and T-memory cells in adoptive antibody formation in mouse bone marrow.

During the secondary response of mice to T-dependent antigens, antibody-producing plaque-forming cells (PFC) appear not only in peripheral lymphoid organs, but also in the bone marrow. This bone marrow antibody formation is feeble after primary immunization. The capacity of bone marrow antibody formation is dependent on the presence of antigen-specific memory cells at the moment of secondary immunization. We investigated whether hapten-primed B memory, carrier-primed T memory or both B-memory and T-memory cells are required for the adoptive PFC response in the bone marrow to T-dependent hapten-carrier conjugates. Adoptive antibody formation in the bone marrow was found after transfer of hapten-primed spleen cells, but not after transfer of carrier-primed spleen cells or virgin spleen cells. Thus, B-memory cells are obligatory for adoptive antibody formation in the bone marrow, in contrast to T-memory cells. However, T-memory cells did facilitate the bone marrow PFC response mediated by the infused B-memory cells.

Animals↗

HLA antibody formation within the HLA-A1 crossreactive group in multitransfused platelet recipients.

The formation of intragroup antibodies, HLA antibodies directed against antigens in the same crossreactive group (CREG) as those of the serum donor, may be an important cause of transfusion failures in patients receiving HLA-matched platelets. Twenty-two patients whose HLA types included at least one antigen in the HLA-A1 CREG were studied. Of the ten patients who formed HLA antibodies, six produced antibodies that reacted with one or more antigens in the HLA-A1 CREG. Five of 12 patients whose HLA types included HLA-A3 formed antibodies directed against HLA-A1-10-11 or HLA-A1-10. In contrast, only one of ten individuals whose phenotypes included HLA-A1, HLA-A11, or both produced anti-HLA-A3. Eleven incompatible retrospective crossmatches were observed in recipients of HLA-matched platelets attributable to intragroup antibodies. Patients receiving incompatible platelets had unsatisfactory post-transfusion platelet count increments. It is concluded that intragroup antibodies, such as those directed against antigens in the HLA-A1 CREG, are an important cause of platelet transfusion failures in patients requiring long-term platelet transfusion support. These antibodies can be identified by routinely screening recipient sera for HLA antibodies and performing retrospective crossmatches using the lymphocytotoxicity technique.

Antibody Formation↗

Studies of the mechanism of action of diketocoriolin B to enhance antibody formation.

Diketocoriolin B (DKC), at a very low dose (0.1 micrograms/mouse) or in a low concentration (0.01 ng/culture) augmented antibody formation to sheep red blood cells (SRBC) in vivo and in vitro. The addition of DKC to spleen cell cultures 24 approximately 48 hours after the start of the culture showed the strongest effect. The stimulatory effect was not influenced by the elimination of macrophages. DKC also augmented antibody formation in T cell-depleted spleen cell cultures and in cultures of spleen cells of athymic mice. The treatment of spleen cells with DKC at 37 degrees C or 4 degrees C for 30 minutes before the start of the culture enhanced antibody formation to SRBC. both treatments of macrophage-rich and lymphocyte-rich cells with DKC enhanced antibody formation.

Animals↗

Antibody formation. II. The specific anamnestic antibody response.

Diphtheria toxoid-antitoxin precipitates formed in antitoxin excess can prepare guinea pigs, rats, and rabbits for a secondary type of antitoxin response. Priming may occur without the development of detectable serum antibody. In rats, toxoid-antitoxin precipitates are more efficient than "free" toxoid in priming, whereas in guinea pigs, the magnitude of the anamnestic response varies with the precipitate employed. The possibility that priming is due to "free" antigen released from the specific precipitate rather than the precipitate itself is discussed. The anamnestic antitoxin response can be inhibited by passive antitoxin, but less efficiently than primary antitoxin formation. Partial suppression of the secondary antitoxin response was accomplished by injection of excess horse antitoxin as long as 4 days after reimmunization with toxoid. The importance of these findings for the understanding of passive-active immunization in the human is discussed.

Animals↗

[Studies of D-penicillamine (4) : effects on antibody formation (author's transl)].

The value of D-penicillamine (D-PA) in the treatment of rheumatoid arthritis is now well established, however, the mode of action remains obscure. We studied the effects of D-PA on the primary and secondary homocytotropic antibody formation with various doses, timing, quantity of antigen stimuli and stress loading in mice. Homocytotropic antibody was assayed by rat PCA (IgE) or mouse PCA (IgG1), and the effects were compared with those of the other antirheumatic drugs such as aurothiomalate and chloroquine diphosphate and the immunosuppressive agents such as hydrocortisone and cyclophosphamide. The antibody formation was slightly suppressed by D-PA under various conditions induced by different quantities of antigen stimuli, while the effects of the other antirheumatic drugs and the immunosuppressive agents on the primary and secondary responses differed from that of D-PA. Stress loading applied with oral consecutive administration of saline for 3 weeks or by restraint with adhesive plaster from 3 days before the primary immunization reduced the antibody formation. D-PA restored the reduced IgE antibody formation after the secondary immunization and also weight of the spleen. These observations suggest that D-PA acts as an immunomodulating agent as the spleen weight and IgE antibody formation were recovered under conditions of induced stress.

Animals↗

Suppression of reaginic antibody formation in guinea pigs by anti-idiotypic antibodies.

Syngeneic immunization of strain 2 and strain 13 guinea pigs with purified antibodies against benzyl-penicilloyl bovine IgG (BPO-BGG) produces anti-idiotypic antibodies which specifically inhibit antigen-induced T cell proliferation in vitro. In sensitized guinea pigs, passive administration (either intravenously or subcutaneously in complete Freund's adjuvant [CFA] of these anti-idiotypic antibodies has a reversible suppressive effect on IgG and IgM responses. In addition, preimmunization with idiotypes effects a long-term and specific suppression of the production of homocytotropic antibodies against a hapten-protein conjugate (BPO-BGG). The suppression of the homocytotropic antibody response in already sensitized outbred guinea pigs was attampted by immunization with autologous serum, autologous antibodies, or autologous lymphoid cells. With all immunization procedures used so far, no significant suppressive effects could be demonstrated. The significance of these findings, in terms of the practical potential of autoanti-idiotypic immunization for the management of allergic diseases, is briefly discussed.

Animals↗

Effect of colchicine on the antibody response. I. Enhancement of antibody formation in mice.

Colchicine (CC) enhances the antibody response in mice to protein antigens, like diphtheria toxoid and human gamma globulin, as well as to the 2,4,6-trinitrophenyl hapten. Maximal enhancement was observed when CC was administered to animals on the same day as the injection of antigen. The optimal dose of CC was in the range of 1.0-1.5 mg/kg body weight. The enhanced antibody formation was evident from elevated circulating antibody titers and from an increased number of antibody plaque-forming cells (PFC) of the spleen. The circulating antibody titer of CC-treated animals was higher than that of control animals by a factor of about 3-7 in the primary response, and by a factor of at least 15 in the secondary response. In terms of the number of antibody forming cells, CC enhanced the primary PFC response by approximately equal to 100%, and the secondary PFC response by as high as fivefold. The enhancing effect of CC seemed to be related to its mitosis-blocking capacity since (a) vinblastine another antimitotic drug, was found to be as effective as CC and (b) lumicolchicine, the non-anti-mitotic structural isomer of CC, was ineffective in potentiating antibody responses. The critical timing in the administration of CC on the same day as antigen suggests that most likely, the mitotic poison was acting on antigen-stimulated early dividing suppressor cells.

Animals↗

Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejection in rats by suppression of antibody formation.

This study provides evidence of antibodies playing an important role in hamster-to-rat cardiac xenograft rejection and discusses the use of 15-deoxyspergualin (DSG) to suppress this first-set rejection, as well as hyperacute rejection induced by sensitization. The effect of recipient splenectomy (Spx) as an adjuvant to DSG to control first set xenograft rejection was also examined. When hyperimmune serum was taken from control recipients at rejection time and injected i.v. into new recipients of cardiac xenografts, hyperacute graft rejection resulted. Survival depended on the amount of serum injected and ranged from 14.7 +/- 2.5 min with 3 ml of serum to 233.3 +/- 61.1 min with 0.5 ml. Experiments on first-set xenograft rejection revealed that a dose of 2.5 mg/kg/day DSG could prolong xenograft survival from 3.4 +/- 0.5 days in untreated controls to 9.5 +/- 2.6 days (P less than 0.01). A dose of 5 mg/kg/day DSG, though it increased graft survival to 16.4 +/- 5.9 days, proved to be toxic to the recipients. Spx alone prolonged xenograft survival to 5.2 +/- 0.4 days, and, when combined with 2.5 mg/kg/day DSG administration, prolonged graft survival to 22.1 +/- 5.5 days (P less than 0.01 vs. DSG alone). The appearance of cytotoxic antibodies was delayed, and titers decreased from 1:256 in untreated controls to 1:16-1:64 both in the group that underwent Spx only and in the group that received 2.5 mg/kg/day DSG. Combined treatment suppressed antibody response for more than two weeks. Experiments on hyperacute rejection induced by sensitization revealed that 1 ml of hamster whole blood transfused into prospective heart recipients 1 week before grafting resulted in graft loss in 18.2 +/- 6.1 min. Pretransplant transfusion and concomitant daily administration of 5 mg/kg/day DSG until one day after grafting not only prevented hyperacute rejection but prolonged graft survival to 7.0 +/- 0.7 days. This survival was significantly longer than with DSG alone (4.2 +/- 0.8 days, P less than 0.01). We concluded that the marked suppression of antibody formation by DSG plays a major role in preventing first-set xenograft rejection and hyperacute rejection induced by sensitization.

Animals↗

The region 0.7615-0.796 m.u. of the HSV-1 genome determines suppression of humoral antibody formation against herpes simplex virus.

The influence of genetic properties of parts of the HSV-1 genome on suppression of humoral antibody formation was investigated by using intratypic recombinants. The deleted strain HFEM (HSV-1) induces suppression. The MluI DNA fragment (coordinates 0.7615-0.796 m.u.) derived from the antibody inducing strain F1 (HSV-1) was transfected into the deleted strain HFEM to produce the recombinant virus R-M1CI and shown to restore antibody formation, as demonstrated by neutralization- and ELISA-tests. The intratypic recombinant viruses R-15, R-19 and R-26, produced by transfection of the Bam HI DNA-fragment B (0.738-0.809 m.u.) of strain F1 into the deleted strain HFEM, resulted in antibody formation only in the recombinant virus R-26. The reason for these different properties might be associated with the presence of small deletions in the SmaI A-fragment (0.763-0.765 m.u.) or elsewhere in the Bam HI DNA-fragment B. Our results were finally correlated to replication of the recombinant viruses in macrophages and to spread into spleen and adrenal glands. There is evidence that antibody formation may be correlated to the ability of HSV to replicate in macrophages.

Adrenal Glands↗